UK Pavilion: BIO International Convention 2023

5–8 June 2023

Hall B, Stand 2348

Boston, Massachusetts

Foreword

It is an exciting time for life sciences globally and nowhere more so than in the UK, where our life sciences sector is the jewel in the crown. The UK’s strong heritage of scientific discovery, supported by world-class research institutions and talent, meets a vibrant biotech venture innovation ecosystem and one of the world’s leading hubs of capital investment in the City of London – with the golden thread of the NHS running throughout to create an inspired, innovative and international life sciences industry.

Lord Johnson Minister of State Department for Business and Trade

The UK and Boston are life sciences powerhouses, making significant advances in science and medicine. We are taking already strong links to a new level with the establishment of the UK-Boston Biotech Corridor, better connecting these two global centres of excellence as a launchpad for increased biotech investment, talent and trade.

This corridor will help serve as a gateway for British businesses to the wider US market, where life sciences is already one of our top exports, and for US companies to invest and leverage the UK as a gateway to the world.

Life Sciences is a strategic priority for Government. We are working to take UK Life Sciences to new heights, ensuring that the UK is a globally leading location for innovation and investment, and is prepared to export cuttingedge solutions to the world.

In 2021, we published our vision for the Life Sciences sector –an ambitious 10-year plan for how the Government, sector and NHS will work together. We want to work with industry to address the biggest threats to health globally, building on the success of our response to the Covid-19 pandemic.

From being the first country globally to approve a Covid-19 vaccine for emergency use to our accelerated vaccination programme, and rapid clinical trials that helped to identify therapies, imagine the potential if we can apply this way of working to great healthcare challenges such as cancer, obesity, dementia, addiction and mental health –the possibilities are endless.

Innovative

The NHS is central to this vision. As a key innovation partner to industry, combining deep clinical expertise, trial and deployment platforms at scale, with longitudinal data from a diverse population of more than 65 million people. With 1.6 million patient interactions every 24 hours, an unparalleled level of information is generated alongside the routine business of delivering care – no other healthcare system in the world offers this level of insight into our health. We want to work with the global life sciences sector to maximise the potential of the NHS as a partner to enable and accelerate research and innovation.

Our science and universities are renowned – with 4 of the Top 10 universities in the world for life sciences and medicine – and a pipeline of new talent on the horizon. The UK Biobank continues to be a unique research and discovery resource for the world, while Our Future Health will bring together up to five million people to develop new ways to prevent, detect and treat diseases.

The industry is maturing, with more than 282,000 people employed across the UK in

more than 6,500 life sciences businesses, and sector turnover grew to £94 billion in 2021. The world’s Top 25 biopharma companies all operate in the UK, and the UK ecosystem offers an expert services and supply chain across the lifecycle of product development and delivery.

The combination of Government support, unparalleled science, access to the world’s largest single healthcare system, and the deepest capital markets in Europe have created an environment where biotechs can thrive. More than any single US city, London sits at the confluence of tech, bio and finance. This is why the UK is home to 1 in 3 biotechs founded in Europe in the last decade, and holds the leading position in Europe for life sciences finance, accounting for more than a third of total venture capital raised and over half of the total deals recorded in 2022.

Pair this collaborative ecosystem with an improving business environment, clinical trials and regulation, and with the UK’s extensive global network and influence and you have a highly competitive life sciences investment destination, and strong foundation for export.

International

Whether you are looking to access talent, good value for your business, or supercharge your research enterprise, you will find ample opportunity to locate, partner and innovate right across the UK. Moderna is building their new Innovation and Technology Centre on the Harwell campus. In Stevenage, the Cell and Gene Therapy Catapult anchors Europe’s largest advanced therapies cluster. In Liverpool, access world-class disease and vaccines research, or trial and make vaccines in a highly connected, collaborative environment.

We invite you to visit the UK Country Pavilion during BIO week and take a look at the best of our dynamic life sciences clusters across all four corners of the UK – in England, Northern Ireland, Scotland, and Wales. Over the course of the week, the Pavilion will host 20 exciting companies and we’ll be showcasing UK innovation, expertise, and scientific creativity.

Come and visit the UK Pavilion in Hall B, Booth 2348 to start your conversation with the UK. We look forward to engaging with you in Boston.

We look forward to seeing you soon.

If you have any queries about the UK at BIO, please contact DITLifeSciences@brayleinoevents.com

Why the UK?

The UK Life Sciences sector is vibrant and growing.

A global life sciences hub

• The UK is home to more than 6,500 life sciences companies employing over 280,000 people

• Cambridge and Oxford are respectively ranked 1st and 5th globally as clusters for science and technology intensity

• More than 50% of sector employment is located outside of London and the South East

Lowest Corporation Tax rate in the G7, and attractive reliefs for R&D and capital allowances

A top destination for life sciences VC

• 4th largest cluster in the world for life sciences VC in 2022 after China, Massachusetts and San Francisco

• In 2022, the UK attracted more than a third of total VC raised by European companies and over half of the total deals in the sector

• UK biotech saw record breaking leaps in finance between 2012 and 2021, growing more than ten-fold

• All Top 25 global companies operate in the UK, and newer entrants too

A long-term Life Sciences developed with the of a strong partnership

High impact education

• Home to 4 of the universities for life

• Highest government research in Europe

• 13.4% of graduates education graduating sciences, mathematics programmes in amongst comparator

A global innovation

• Ranked 4th globally Global Innovation

• Home to 1 in 3 of ups founded in

• The largest biomedical across all stages

Home to the world’s cell and gene therapy

Why the UK?

Sciences Vision the sector, illustrative partnership working approach

education and research

the Top 10 global life sciences and medicine government spending on health Europe and 3rd globally graduates from tertiary graduating from natural mathematics and statistics 2019, 2nd globally comparator countries

World first research endeavours at scale: Having established the UK Biobank, 100,000 Genomes Project, and Our Future Health. Ambitious diverse genome and newborn sequencing efforts are now underway, and Our Future Health will recruit up to 5 million people to develop better ways to prevent, detect, and treat diseases.

The NHS is globally unique

• The NHS acts as an innovation partner to industry

• Longitudinal data resources from a diverse population of more than 65 million

• 1.6 million patient interactions every 24 hours

• First national health system in the world to introduce whole genome sequencing into routine care

innovation hot spot globally in the 2022 Innovation Rankings of the life sciences startEurope in the last decade biomedical pipeline in Europe stages of development Booming exports and inward investment

world’s 3rd largest therapy cluster

• Exported £24.2 billion worth of life sciences goods around the world in 2021

• Ranked 3rd in the world for number of inward investment projects in 2021

• All Top 25 global companies operate in the UK, and newer entrants too

Welcome to the UK Pavilion at BIO 2023

We are delighted to showcase UK Life Sciences on our grand UK Pavilion at BIO 2023.

The UK provides a globally unique environment to accelerate medical breakthroughs and shape the future of global healthcare. Nowhere else in the world do you have access to a national healthcare service serving a population of 65 million, worldleading academic institutions and industry, supported by a dynamic medical regulator and some of the richest healthcare datasets in the world, not to mention some of the deepest capital markets in Europe. The impact of this collaboration between industry, Government and academia was clear during the UK’s leading research and innovation response to COVID-19,

with the UK leveraging the structural pillars of its life sciences sector to tackle a global health problem. The UK has sought to build on its scientific successes during the pandemic with the Life Sciences Vision, which sets out a mission-based approach to tackling the great healthcare challenges, calling for innovative industry leaders to direct their creativity and resources to the prediction, early diagnosis and prevention of chronic diseases.

The Vision also sets out how the Government is committed to making the UK a globally leading location of life sciences investment and innovation and cement our position as a global Science Superpower.

Come and join us at the Pavilion to meet the UK delegation of innovative companies and public sector organisations, representing the very best of UK innovation.

There are few places in the world that can rival the UK for the density of its life sciences sector. The Crick Institute, Europe’s largest biomedical research centre is just a stone’s throw from Google’s DeepMind AI campus in London, which in turn is 30 mins by train from Europe’s largest cell and gene therapy cluster in Stevenage and an hour’s flight from Edinburgh’s Bioquarter – a 167-acre site for life sciences research and development. There is a huge amount of activity and innovation packed onto a relatively small island with great connectivity nationally and internationally. We are delighted to have representation from all corners of the UK on our Pavilion this year, including Scotland, Wales and Northern Ireland and Harwell campus in Oxfordshire offering a range of expertise across the life sciences sector.

Come and meet us at BIO to find out more about UK life sciences; whether you’re a UK SME, an international company looking to do business with the UK or part of an international delegation, we are eager to connect with you over the course of the week.

Northern Ireland Transforming lives through science

Northern Ireland’s cluster of innovative companies has capabilities spanning the complete drug development value chain. The region is a prime location to partner and co-locate with leading companies and research centers across a range of specialisms including cancer, cardiovascular disease and respiratory conditions.

The region offers businesses a unique combination of:

• Exceptional talent

• Competitive costs

• World-class research

• EU regulatory alignment

• Innovative and collaborative infrastructure

• Barrier free access to UK and EU markets

Visit us at Bio International Convention on the UK Pavilion, stand 2348 to learn how Northern Ireland delivers for your business.

Partners

Invest Northern Ireland

www.investni.com

www.linkedin.com/company/invest-northern-ireland/

As the regional business development agency for Northern Ireland, Invest Northern Ireland’s role is to grow the local economy. We do this by helping new and existing businesses to compete internationally, and by attracting new investment to Northern Ireland. Northern Ireland is a prime location for Life and Health Sciences businesses, thanks to its unique combination of talented people, world-class research, and an ecosystem that benefits from a strong collaborative approach between industry, academia, and clinicians in the commercialisation of innovative research. The region is home to more than 250 Life and Health Sciences companies who can support all aspects of your drug development cycle, from discovery through preclinical and clinical research, to commercial manufacturing and lifecycle management. Northern Ireland continues to play a key role in solving global healthcare challenges through innovation, with businesses of all sizes focused on advancing pharmaceuticals, diagnostics, precision medicine, connected health, and medical devices.

Northern Ireland provides an opportunity to capitalise on cutting-edge technology and to partner with local expert companies to develop, test, validate, and commercialise advanced therapeutics, biomarker assays and precision diagnostics, accelerating precision medicine applications. Queen’s University Belfast and Ulster University, Northern Ireland’s two major universities, provide globally competitive research expertise, along with 17 life sciences-related Centres of Excellence with over 1,000 researchers.

To find out more about the Northern Ireland companies at BIO visit: http://investni.com/bio

Michael Conlon Business Development Executive

+1 646 715 7995

michael.conlon@investni.com

Philip McCann International Trade Adviser – Life & Health Sciences

+44 (0)75 8513 9612

philip.mccann@investni.com

Scottish Development International is the Scottish Government's international economic agency. Our mission is to support more Scottish companies to think, trade and compete globally, and attract quality investment into Scotland.

Discover more. Visit us at stand 2348.

Scottish Development International

www.sdi.co.uk

www.linkedin.com/company/scottish-development-international/

Scottish Development International (SDI) is part of Scotland’s main enterprise, innovation, and investment agency. We help international companies find partners in Scotland, and Scottish companies develop their business overseas. SDI also works to attract inward investment and knowledge to Scotland.

With more than 700 organisations and 41,000 people, the Life Sciences sector in Scotland has strengths in Drug Discovery and Development, Precision Medicine, Digital Health, Diagnostics, and Advanced Therapy Medicinal Products. There are leading companies, an availability of talent, a supportive ecosystem, academic excellence, and a connected supply chain.

With a global network of offices, including in Boston and San Jose, and across Europe and Asia, SDI provides a wide range of services. These include connecting international companies to the Life Sciences sector in Scotland by identifying the right partners, scoping incentives, business mentoring, market intelligence, business location information and investor aftercare.

OUR SERVICES – providing essential market information and acting as a single point of contact for access to Scottish knowledge and expertise including Scottish companies, research and clinical organisations, the Scottish Government, public agencies, funding support and potential investors.

To find out more, visit www.sdi.co.uk and www.lifesciencesscotland.com

Wales

www.tradeandinvest.wales/

www.linkedin.com/showcase/trade-&-invest-wales/

The Welsh Life Sciences industry currently employs more than 12,000 people, in over 260 companies ranging from SMEs and start-ups to large blue chips, with an approximate turnover of £2.6 billion. With worldleading academic expertise and a central Life Sciences Hub, Wales demonstrates a strong competitive advantage in Medtech, Diagnostics, Wound Healing, Regenerative Medicine and Cell Therapy and is already creating a world-leading Regenerative Medicine ecosystem, which includes academics, the NHS, Government and centres of excellence. 75% of the life sciences market is export focused. Welsh companies are supplying their products and services to markets all around the World.

Richard Harris

Head of Trade

+ 44 (0)7891 423903

Richard.Harris@gov.wales

Jonathan Fortune

Head of Export Services

+44 (0)7342 052916

Jonathan.Fortune@gov.wales

Co-exhibitors on the UK Pavilion

This year we are showcasing 20 innovative UK Life Sciences organisations from across the regions. See who will be exhibiting on the Pavilion and connect with them via the BIO One-to-One Partnering.

Cancer Research Horizons

Cancer Research Horizons is the innovation arm of Cancer Research UK – the world’s largest charitable funder of cancer research. We bring together world-leading minds, bold ideas and the right partners to bridge the gap between academic research and taking drugs to market. We focus on the tougher, more profound ideas that can lead to true innovation, translating them into effective treatments and diagnostics for cancer patients. To date, we’ve played an instrumental role in forming over 60 spin-out companies. We’ve helped bring 11 cancer drugs to market, borne out of Cancer Research UK’s pioneering research. Through these drugs, we have enabled in excess of 6 million courses of treatment for cancer patients across the world. With access to Cancer Research UK’s network of 4,000 exceptional researchers and clinicians, and £300+ million of annual research spend, we’re a powerful partner in the fight to conquer cancer.

We are Cancer Research UK‘s innovation arm. Our expertise in cancer drug discovery, clinical development and commercialisation has resulted in over 60 successful spin-out companies and 11 marketed drugs.

+44 203 469 6608

george.tzircotis@cancer.org.uk

Cell and Gene Therapy Catapult

www.ct.catapult.org.uk/

www.linkedin.com/company/cgt-catapult/

The Cell and Gene Therapy Catapult is an independent innovation and technology organisation committed to the advancement of cell and gene therapies with a vision of a thriving industry delivering life changing advanced therapies to the world. Its aim is to create powerful collaborations which overcome challenges to the advancement of the sector. With over 400 experts covering all aspects of advanced therapies, it applies its unique capabilities and assets, collaborates with academia, industry and healthcare providers to develop new technology and innovation. The Cell and Gene Therapy Catapult works with Innovate UK. For more information, please visit ct.catapult.org.uk or visit http://www.gov.uk/innovate-uk.

We’re a team of experts covering all aspects of advanced therapies. Through our unique operating model, we collaborate with companies, researchers and innovators to accelerate cell and gene therapies to market, from process development to clinical adoption, finding solutions to ATMP challenges across the cell and gene therapy life cycle.

John Kelly Head of Transactions

info@ct.catapult.org.uk

Marzena Flasza-Baron

Business Development Manager – International info@ct.catapult.org.uk

Clyde BioSciences Limited

www.clydebio.com/

www.linkedin.com/company/clyde-biosciences-ltd/

Clyde Biosciences specializes in measuring and interpreting drug effects on cardiac cell function at clinically relevant doses. The company’s proprietary technology combines a range of human stem cell and other relevant in vitro phenotypes with a sensitive, data-rich measurement system and expert interpretation. The platform is demonstrably capable of screening-level throughput providing a more complete assessment of cardiovascular efficacy and safety with in vivo and clinical predictability.

Clyde’s CellOPTIQ® platform generates human relevant cardiomyocyte functional data to enable faster, safer, and more accurate development of new medicines, reducing cost and increasing success.

Clyde is the only validated CRO for the CiPA Assay.

Richard Henderson

Chief Executive Officer

+44 771 787 8188

rdh@clydebio.com

Mark Bryant

Chief Business Officer

+44 780 181 6212

mb@clydebio.com

Cumulus

www.cumulusneuro.com/

www.linkedin.com/company/cumulusneuroscience/mycompany/

Cumulus Neuroscience provides a reliable real-world multimodal digital data acquisition and analytics platform and end-to-end services and solutions for CNS clinical trials. Our platform is designed to be the goldstandard for CNS assessments, providing the critical data and insight needed for faster, more robust and cost-effective clinical trials that improve the delivery of new therapies to patients. We provide frequent at-home acquisition, combining neurophysiological monitoring (EEG) time-linked with a range of assessment tools, including cognition, mood, language and sleep. The frequent remote assessment significantly lowers patient burden and allows aggregation of multiple sessions to account for dayto-day cognitive fluctuation. Cumulus was formed in collaboration with leading global pharmaceutical companies to meet the industry’s complex clinical trial needs with a pharma advisory consortium, and Cumulus’ platform is currently deployed in clinical trials for neurodegeneration and neuropsychiatric diseases.

Cumulus is a full-service digital data acquisition and analytic solutions provider with an at-home, real-world multimodal platform for use in CNS clinical trials. The flexible Cumulus platform allows frequent, low patient burden assessment of cognition, mood, language and sleep enabling sensitive and accurate patient monitoring and precision care.

Aman Bhatti Chief Executive Officer

+1 201 572 9409

aman@cumulusneuro.com

Shani Waninger

Vice President, Biopharma Business Development

+1 858 342 5044

shani@cumulusneuro.com

Domainex

www.domainex.co.uk

www.linkedin.com/company/domainex

Domainex is a multi-award-winning integrated drug discovery research service partner, which provides the full range of pre-clinical drug discovery services. We work collaboratively in partnership with clients from a variety of sectors including academic, pharmaceutical, biotechnology and patient foundation organisations around the world. Our team comprises of over 90 scientists, who are committed to providing high-quality services, and have expertise in:

• Protein production and characterisation

• Structural biology: X-ray crystallography and cryo-EM

• Assay development and screening (biochemical, biophysical and cell assays)

• High-throughput screening (HTS)

• Computational chemistry including virtual screening

• Medicinal, synthetic and analytical chemistry

• Fragment- and structure-based drug discovery

We have an excellent reputation; >80% of our clients signed up for extensions or additional studies in 2022 and >95% stated they would recommend us to someone in their professional network.

Contact us at enquiries@domainex.co.uk to speak to one of our experts.

Domainex is a multi-award-winning, integrated drug discovery research service partner, which provides the full range of pre-clinical drug discovery services to support its clients from gene nomination through to candidate drug selection.

Catherine Stace Executive Vice President, Business Development

+44 774 813 7434

catherine.stace@domainex.co.uk

Ray Boffey Executive Vice President, Medicines Research and Strategic Alliances

+44 750 342 0412

ray.boffey@domainex.co.uk

Fusion Antibodies

www.fusionantibodies.com

www.linkedin.com/company/fusion-antibodies-plc/

Fusion Antibodies is a contract research organisation, which designs, and optimises therapeutic antibodies for the healthcare market. We help clients solve complex, challenging problems throughout their early discovery antibody programs. Our expertise is defined by our experience. Unique process frameworks, and technology platforms, enable our clients to develop therapeutics within the most challenging modalities and diseases. Guiding clients through early-stage antibody discovery, in the most efficient and effective way, we enable biotechnology and pharmaceutical organisations towards their end-goal – the provision of treatments that improve the lives of patients worldwide.

As an independent team, we offer flexibility and agility that antibody discovery and development programs require. Our approach to projects considers long-term impacts on safety, efficacy, and manufacturability at every stage, de-risking antibody programs and maximizing success. As an early discovery partner, our scientists increase the pace of the clinic by guiding clients to develop the best antibodies possible.

Fusion Antibodies provide clients with antibodies that have a superior probability of reaching the patients. Our services include scientific consultancy, target validation, antigen design, unique antibody discovery platforms and libraries, antibody engineering services, generation, development, production, characterization, optimization and stable cell lines production. Challenge Us to progress your molecule.

+44 770 633 2970

Britney.Alexander@fusionantibodies.com

+44 289 043 2800

jenna.hewitt@fusionantibodies.com

G&L Healthcare Advisors

www.gandlhealth.com

www.linkedin.com/company/g-l-health

G&L Healthcare Advisors uses subject matter expertise and decades of experience gained in every aspect of Regulatory Affairs, Quality Assurance and Clinical Development to meet the challenges faced by healthcare companies globally.

From product development and submissions to company-wide change management, we design, implement, and run quality, results-focused outcomes for all our clients.

Our innovative solutions and services support clients at all stages of the development to deliver meaningful change for the better.

Kevin O’Toole Vice President, Business Development

+44 203 143 2185

kotoole@gandlhealth.com

Kevin O’Beirne Director, Business Development

+1 908 402 6908

kobeirne@gandlhealth.com

www.integrity.net

www.linkedin.com/company/integrity-project-solutions-limited-ipsl/

Formed in 1998, Integrity is a Life Science consulting organisation who are passionate about helping customers innovate and advance treatments for the well-being of the society. We help our clients plan and implement digital strategies and solutions that dramatically accelerate drug and device development, and optimise manufacturing, supply chain and quality processes. By combining intelligent risk-based thinking with real-world expertise, we efficiently implement and validate digital solutions in accordance with regulatory expectations.

We are proud to have established long-term partnerships with our clients through close working relationships and successful outcomes. These partnerships continue to provide valuable insights which we carry with us as we navigate the changing business landscape.

• We are a leading global life sciences consultancy with a wealth of real-life experience in Pharma, Biotech and Devices.

• We help research and development, manufacturing, logistics and vendor organisations innovate to drive their businesses forward.

• We enable innovation through a pragmatic and intelligent risk-based approach.

• We have a team of highly skilled professionals who provide a blend of business knowledge and subject matter expertise.

We are your partner and your expert, helping you implement the right projects in the right way – delivering change you can trust.

Paul James-Martin Chief Financial Officer

+44 127 674 0531

paul.james-martin@integrity.net

Chris Reid Chief Executive Officer

+44 127 658 2123

chris.reid@integrity.net

MEU

www.meu.org.uk/

www.linkedin.com/company/medicines-evaluation-unit/

Medicines Evaluation Unit (MEU) Ltd is one of the UK’s leading CROs, a facility where commitment to excellence is paramount. MEU possess extensive pharmaceutical, scientific and clinical expertise, allied with fast volunteer recruitment, within a state-of-the-art hospital-based research facility.

MEU offer products and services to enable better, safer and more efficient study designs, particularly in complex patient groups. MEU’s bespoke, phenotyped database and trial management system (ICARUS), assists rapid study recruitment ensuring we meet our clients’ timelines. ICARUS possesses over 32,000 active volunteer profiles and enables MEU to assess protocol inclusion criteria, and accurately provide real-time feasibility.

MEU has a team of experienced Principal Investigators led by the worldrenowned respiratory KOL Professor Dave Singh, MEU Medical Director. To accelerate drug discovery, MEU have a host of human lung tissue models for target identification and validation studies. The techniques used include cell culture, immunoassays, immunohistochemistry, PCR and flow cytometry.

The majority of our studies are Phase I – III (inc. FIH & FIP), in both healthy volunteers and the following therapeutic areas:

• Respiratory (Asthma, COPD, Cough, CF, ILD/IPF)

• Dermatology (AD, Psoriasis, Urticaria)

• Endocrine (Graves’)

• Cardiovascular (Hypertension

• Renal (CKD)

David Rogers

Chief Executive Officer, MEU

+44 798 000 0037

drogers@meu.org.uk

Liz Batty

Clinical Director

+44 796 602 1717

lbatty@meu.org.uk

Micropore Technologies

www.microporetech.com

www.linkedin.com/company/icropore-technologies-ltd/

Micropore Technologies offers savings in development time, increased yields and simplified operation for those engaged in development and manufacture of parenterals, particularly nano-and micro-sized particles for application in LNPs, PNPs, Polymer microspheres (eg PLGA, PLA), Hydrogels, and many others. We also support our clients with their GMP qualification requirements.

Headquartered in the UK, Micropore has offices in USA and India and has agents in Japan and Australia.

Micropore is a technology provider for complex drug formulations including LNPs and long acting injectables. It has a unique membranebased approach that is seamlessly scalable from initial experiment to fully scale manufacturing. Extremely low energy and low shear are defining features which help to deliver significant benefits to our customers.

Dai Howard Chief Executive Officer

+44 788 883 3859

dai.hayward@microporetech.com

Kendall Murphy

Business Development Manager

+1 (606) 231-6829

kendall.murphy@microporetech.com

www.obn.org.uk

www.linkedin.com/company/9470766/

OBN’s core purpose is to catalyse success in UK life sciences, and as a not-for-profit member organisation everything we do is focused on helping our Members and the sector to thrive. Our membership of 460+ companies and organisations is spread across the UK with many in the Golden Triangle of Oxford, London and Cambridge. Members include pharma, biotech/medtechs, CXO’s, investors and associated industries (legal, IP, HR, PR etc). Becoming an OBN Member opens the door to a broad range of opportunities to catalyse your growth: via networking/partnering, our purchasing consortium, training and our consulting services. Our largest event is BioTrinity, an annual partnering and investment conference aimed at Series A companies, that attracts the best of life sciences in the UK. So if you are seeking connections in the UK life sciences sector, come and talk to us! Your success is our success.

OBN is a not-for-profit membership organisation providing connectivity and services across the breadth of the UK life sciences sector.

Becoming an OBN Member opens the door to a broad range of opportunities to catalyse your growth: via networking/partnering, our purchasing consortium, training and our consulting services.

+44 781 086 3370

emma.durham@obn.org.uk

+44

jonathan.rohll@obn.org.uk

ONIX Life Sciences

(now part of Framework Solutions)

www.framesol.com

www.linkedin.com/company/framework-solutions-inc-/

Onix Life Sciences was born twelve years ago in the UK, specializing in regulatory affairs, regulatory operations like CTIS uploads for clinical trials & eCTD publishing. In March 2023 Onix was acquired by Framework Solutions LLC.

Framework Solutions provides Clinical to Commercial Solutions to Biotechnology, and Pharmaceutical Companies with the goal of accelerating customer success. We provide both Strategic and Tactical Solutions in the areas of Medical Affairs, Regulatory, MLR, and Commercialization. These areas are supported by our Technology Group which offers tech-enabled solutions and integrated enterprise help desk/infrastructure support.

We have provided services to over 225 clients ranging from Emerging Biotech to Large Pharma. We deliver these services globally with operation centers in North America, Europe, and Asia.

Transformation through Collaboration. Regulatory Medical Legal and regulatory affairs review, Medical Affairs, Commercial Technology, Global Recruiting.

Christene Grew Director of Regulatory Affairs

+44 773 210 9306

cg@onixls.com

Russ Belden Commercial Expert

rbelden@framesol.com

Pangaea Data

www.pangaeadata.ai

www.linkedin.com/company/pangaeadata/

Pangaea is a South San Francisco and London based provider of a novel AI-driven product for characterizing patients across 4,000 hard-to-diagnose conditions in a privacy-preserving and scalable manner, which is helping clinicians in the pharmaceutical and healthcare industry. Pangaea has clinically proven to discover 22x more undiagnosed, misdiagnosed and miscoded patients along with new insights; halve treatment costs; and drive sustainable collaborations between healthcare and the pharmaceutical industry. The founders (Dr. Vibhor Gupta, Prof. Yike Guo) have attracted $200 million through research and are advised by Lord David Prior (former Chairman of NHS England), Mr. Andy Palmer (former Head of Systems Integration at Novartis) and Dr. Thomas Dyrberg (former Managing Partner, Novo Holdings). Pangaea was awarded top-tier status by Microsoft, which is exclusive for 30 of the 30,000 companies they work with and has provided the opportunity to apply its product across 140,000 healthcare providers globally.

Pangaea’s novel AI-driven product characterizes patients across 4,000 hard-to-diagnose conditions in an evolving, privacy-preserving and scalable manner, which has clinically proven to discover 22x more undiagnosed, misdiagnosed and miscoded patients along with new insights; halve treatment costs; and drive sustainable collaborations between healthcare and the pharmaceutical industry.

Vibhor Gupta

Chief Executive Officer and Founder

+44 781 636 5487

www.mwhalley@pangaeadata.ai

+44

www.jzhang@pangaeadata.ai

Seda Pharmaceutical Development Services

www.sedapds.com/

www.linkedin.com/company/9470766/

Seda Pharmaceutical Development Services provides integrated Pharmaceutical Development and Clinical Pharmacology services to the Biotech sector. We enable rapid and efficient development of optimal medicinal products, from conventional to complex, through pragmatic and coherent scientific excellence. Seda was founded in 2015, and has since demonstrated exceptional growth and expansion in our capabilities which include consultancy, laboratory, and pharmacokinetic modelling services. We provide clients with the experience and expertise found in the development functions of major pharmaceutical companies but with the speed and flexibility required by fast-moving Biotechs. Headquartered in Greater Manchester, UK, our bespoke laboratory and office complex is well equipped for the rapid design, development and evaluation of prototype formulation options, from pre-formulation services to the development of preclinical and clinical formulations. Enhancing the value proposition of our clients is our contribution to bringing new, innovative therapies to patients rapidly and successfully.

Unique integration of clinical pharmacology and pharmaceutical development supports drug product design alongside optimal clinical performance and manufacturability. Our expertise includes oral, injectable and targeted drug delivery systems for synthetic small molecules and complex medicines, from the discovery phase, through first-in-human studies and onwards to product approval.

Paul Dickinson Chief Scientific Officer and Co-Founder

+44 754 048 8390

kati.dematas@sedapds.com

Marcel De Matas Chief Technical Officer and Co-Founder

+44 770 242 3406

marcel.dematas@sedapds.com

www.touchlight.com

www.linkedin.com/company/touchlight-ltd/

Touchlight is a privately-owned CDMO based in London, UK, focused on the provision of DNA services and manufacture of enzymatically produced doggybone DNA (dbDNA™) to enable the development of genetic medicines. Touchlight provide rapid, enzymatic DNA development and manufacturing for all advanced therapy production, including mRNA, viral and non-viral gene therapy and DNA API. dbDNA is a minimal, linear, covalently closed structure, which eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies. Clients can be supported from pre-clinical through development and supply, to licencing and tech transfer for use in-house.

Touchlight’s proprietary doggybone DNA is a linear, double-stranded, covalently closed DNA vector, produced through an enzymatic manufacturing process. It can incorporate genes from 500bp to 20kb making it very flexible to support a range of genetic medicines including mRNA, DNA vaccines and viral vectors.

Karen Fallen Chief Executive Officer

+44 771 364 3928

karen.fallen@touchlight.com

Tori Ondo

Sales Manager

+1 858 344 2223

tori.ondo@touchlight.com

UKRI-STFC

www.harwellcampus.com

www.sci-techdaresbury.com/

www.linkedin.com/company/harwellcampus/

www.linkedin.com/company/sci-tech-daresbury/

Harwell Campus is a UK R&D powerhouse and designated Life Sciences Opportunity Zone near Oxford. It’s recognised for world-leading imaging technologies, advancements in xRNA and nucleic acid therapies, vaccines, LNPs, diagnostics and AI-enhanced analytics. Pioneering a multidisciplinary cluster model, Harwell’s Health Tech Cluster brings together industry, academia, public bodies and investors, with £3 billion of open access National research facilities, to commercialise and accelerate innovation. Home to organisations like Moderna, Catalent, Agilent, Vaccitech and Diamond Light Source (UK Synchrotron), Harwell is growing with plans for a further 1.5 m sq.ft. of developments.

Building on this success, Sci-Tech Daresbury proudly hosts England’s north-west Health Tech Cluster. Connecting local and national government, industry, NHS organisations, universities and R&D assets including the Hartree National Centre for Digital Innovation and the Infection Innovation Consortium, it creates a unique matrix, supporting new collaborations and growth.

Adrian Hill Health Tech Cluster Development Manager

+44 792 324 1396

adrian.hill@stfc.ac.uk

Phil Carvil Head of North West Clusters

Philip.Carvil@stfc.ac.uk

Life Sciences Innovator Showcase

Featured Innovators ready to connect with global partners.

Each UK Life Sciences Innovator has a unique

story to tell the world.

The Life Sciences Innovator Showcase is a community of UK companies bringing innovative solutions as they ‘Go Global’ and connect with partners around the world.

These UK Life Sciences Innovators represent UK excellence across the life sciences sector.

The 2023 Showcase includes cutting edge companies across 6 categories:

• Biopharma & Vaccines

• Application, Product & Service Design

• Diagnostics & Precision Medicine

• Digital Solutions

• Medical Technologies

• Medicines Development & Delivery

Find out more at www.lifesciencesinnovator.co.uk

AXOL

www.axolbio.com

www.linkedin.com/company/censo-biotechnology/

At Axol Bioscience, we support your pursuit of more effective, safer therapies. Like you, we believe that having more human-relevant disease models will expand scientific knowledge and de-risk drug development. We use human iPSCs to achieve this and have been doing so since 2006.

We use donated cells from patients and iPSC technology to build physiologically relevant in vitro models.

We have a special focus on neurodegenerative diseases like Alzheimer’s disease as well as cardiotoxicity to promote drug safety.

When working with candidate compounds or novel therapies, our in vitro platforms give you better earlier-stage modeling and safety testing and later-stage efficacy evaluation and improved patient selection.

With these data comes better insights, helping you de-risk projects, reduce costs, and save time during drug development.

At Axol Bioscience, we help your science with better models of human disease.

Better human disease models.

We use iPSCs to build more relevant models of human disease to expand your understanding and de-risk drug development.

• axoCells™ – derived cells

• axoServices™ – outsource your project to the experts

• axoLines™ – human iPSCs from patient and control donors

Ashley Barners Chief Scientific Officer

+44 795 108 6419

ashley.barnes@axolbio.com

Epitopea Ltd

www.epitopea.com

www.linkedin.com/company/epitopea

Epitopea is a recently established cancer immunotherapeutics company based in Cambridge (UK) and Montreal (Canada). We are translating the work of our scientific founders, Claude Perreault and Pierre Thibault who asked: what unique features of cancer cells are visible to T cells and can be targeted for immunotherapies? Using immunopetidomics, our founders discovered mutation-containing tumour-specific antigens (TSAs) detectable by mass spec are rare and dramatically outnumbered by aberrantly expressed or cryptic TSAs arising from a variety of dysregulations common in cancer, such as alternative splicing, dysregulated epigenetic control and loss of translational fidelity. These TSAs have a far greater chance of being shared between patients than mutation-containing TSAs; furthermore, emerging results indicate a great many of them are immunogenic and that they are likely to be amongst the targets exploited by immune checkpoint blockade. Epitopea intends to define and develop a pipeline of therapeutic vaccines for durable cancer control.

• Empirical identification of tumour-specific antigens

• Mass spectroscopy

• Bioinformatics

• Immunopeptidomics

• Tumour immunology

• TCR identification and characterisation

• LNP-mRNA vaccines

Dr Jon Moore Chief Executive Officer

+44 781 790 6145

jon.moore@epitopea.com

Dr Steven Klein Chief Business Officer

+44 795 108 6419

steven.klein@epitopea.com

Oribiotech

www.oribiotech.com/

www.linkedin.com/company/oribiotech-ltd/

Ori is a London and New Jersey based manufacturing technology company pioneering flexible process discovery with seamless translation and scalable commercialization of cell and gene therapies. Ori has developed a proprietary, full stack manufacturing platform that closes, automates and standardizes CGT manufacturing allowing therapeutics developers to develop and bring their products to market at commercial scale. The promise of the innovative Ori platform is to fully automate CGT manufacturing to increase throughput, improve quality and decrease costs by combining proprietary hardware, software, data and analytics. Founded in 2015 by Dr. Farlan Veraitch (UCL), Ori has brought together a seasoned team with over 200 years of combined pharmaceutical, CGT and venture building experience including CEO Jason C. Foster (Indivior), CDOO Kevin Gordon (Tmunity), CTO Stuart Milne (Cytiva), CCO Tom Heathman (Minaris), Chris Mason (AVROBIO), Paul Meister (Thermo Fisher) and Annalisa Jenkins (DimensionTx) alongside expert advisers like Bruce Levine and Robert Preti.

Ori has developed a proprietary, full stack manufacturing platform that closes, automates and standardizes CGT manufacturing allowing therapeutics developers to bring their products to market at commercial scale. The innovative Ori platform automates CGT manufacturing to increase throughput, improve quality and decrease costs combining proprietary hardware, software, data and analytics.

Jason C. Foster Chief Executive Officer

+44 792 027 8334

Jason.foster@oribiotech.com

Phaim Pharma

www.phaim.co.uk

www.linkedin.com/company/phaimpharma/

Phaim is developing novel therapies for the treatment and early detection of autoimmune disease with a lead product in Type1 Diabetes. Phaim’s platform approach to autoimmunity will recapitulate the normal regulatory immune response, preventing the onset of T1DM in prediabetics, and facilitating the use of cellular therapies in the treatment of established T1DM patients.

The platform has means of identifying targets in other autoimmune diseases, such as psoriasis and we would look to produce other therapies after our successful T1DM trial. Furthermore, with our proprietary diagnostic kit, we will be able to predict who is likely to get T1DM and in what time frame.

By doing so, we could potentially treat before the disease develops and look to ameliorate the need for insulin. In short, Phaim can predict, prevent and potentially treat type 1 diabetes and other autoimmune conditions. Phaim’s T1D therapy alone has a potential of world-wide market capture.

Phaim Pharma is dedicated to developing curative treatments for autoimmune disease affecting 5-10% of the global population. It is both a platform and a product company, producing assets for sale or licensing in individual autoimmune diseases with a lead drug in type 1 diabetes.

Dr. Nara Daubeney Chief Operating Officer and Co-Founder

+44 207 351 7011

nara.daubeney@phaim.co.uk

Professor Piers Daubeney Chief Business Officer

piers.daubeney@phaim.co.uk

Spotlight on UK expertise

Featured exporters ready to connect with global partners.

Airfinity Ltd

www.airfinity.com/

www.linkedin.com/company/airfinity-ltd/

Airfinity tracks, predicts and simulates population level disease outcomes in real time to inform decisions that can increase the global life span.

Working with the entire life science ecosystem, Airfinity supports the industry with a suite of proprietary surveillance tools and forecast models to analyse and predict disease outcomes. We use advanced meta science, statistics, epidemiology and machine learning solutions to dynamically understand true disease prevalence and underlying outcome drivers.

By combining this with expert analysis and commentary from our team of scientists, engineers and researchers, we are able to produce actionable insights to reduce health and economic burden.

Airfinity has become the world’s leading source of disease forecasting, specialising in infectious diseases, cardiovascular, metabolic, and renal diseases and other critical areas including RNA.

Airfinity specialises in global infectious disease and pre-emptive health intelligence. By linking data points and building up historical correlation models, Airfinity turns disconnected data into real time predictive indicators, providing near real time data driven assessments of the impact of a new development.

Ane Altuna Oses Business Development Manager

+3 468 071 1947

anealtuna@airfinity.com

Eramol (UK) Ltd

www.eramol.com

www.linkedin.com/company/eramol/

Eramol was founded in the UK by Qualified Persons (QPs) with over 30 years’ industry experience and a shared vision to deliver what the market lacked – high-quality, end-to-end, bespoke clinical contract manufacturing, packaging and global distribution services.

At Eramol, we pride ourselves on adding value to our clients at every critical stage of their journey to a successful clinical study – from regulatory guidance, development services, manufacturing, to labelling and packaging, logistics and specialist supply chain services including UK & EU QP Release.

Eramol’s vertically integrated clinical services enables efficient turnaround for early phase development projects including import, manufacturing and packaging of psychedelics and other narcotics.

With manufacturing facilities in both the UK and Ireland and an established global distribution network, we deliver international clinical trial services that work smarter, more efficiently and more reliably for clients in a complex, fast-changing, post-pandemic world.

• Bespoke manufacturing, packaging & QP release of psychedelics/ Schedule 1 narcotics

• ‘Just in time’, ‘Fast Lane’ packaging & labelling

• API neat-fill capsule manufacturing for rapid early phase supply

• UK/EU importation & QP Release

• Formulation development & QC-testing

• Manufacturing (tablets, liquids and capsules)

• Primary/Secondary packaging & labelling

• Global distribution & logistics services

Peter Mollison Chief Executive Officer

+44 129 336 8080

peter@eramol.com

One Nucleus

www.onenucleus.com/

www.linkedin.com/company/one-nucleus/

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity. Through providing local, UK-wide and international connectivity, One Nucleus seeks to enable our members to maximise their performance. This support helps them achieve, or better still exceed, the goals they have set for themselves. Biomedical and Healthcare R&D have always been impactful in driving social and economic progress.

In an increasingly outsourced, collaborative and multi-disciplinary sector, bringing the best people together is key to translating great innovation into great products that markedly improve patient outcomes and drive economic development. Attracting and enabling the best people to engage with is at the heart of the One Nucleus team ethos and what we continually strive to deliver.

Tony Jones Chief Executive Officer

+44 785 203 0307

tony@onenucleus.com

About the Department for Business and Trade

We are the department for economic growth. We support businesses to invest, grow and export, creating jobs and opportunities across the country.

What we do

DBT is the UK government department responsible for inward investment, export promotion, trade policy and export finance, and the lead organiser of the UK Pavilion and delegation at the BIO International Convention.

We secure UK and global prosperity by promoting and financing international trade and investment and championing free trade. For international partners, we are your front door to the UK. We work through our dedicated and talented teams in the UK and in overseas posts, based at embassies and consulates in more than 100 international markets.

We promote trade and help to open up markets for exporters and to increase UK exports. We are developing the new trade policy framework for the UK as we leave the EU.

Through UK Export Finance, we offer products to exporters and overseas buyers to ensure that no viable UK export fails for lack of finance or insurance.

We are your expert guides on your journey to invest in the UK. We offer free and confidential advice and services to inward investors. We give new investors the confidence to invest in the UK, and we help existing inward investors to expand and grow in the UK and to use the UK as your gateway to the world.

In Life Sciences, we work across the full diversity of businesses operating in the sector and across the full pathway from research through to healthcare delivery.

We collaborate with other parts of government and with our network of sector stakeholders to support the success of the UK life sciences industry, driving improved economic growth and health outcomes.

For more information, contact:

lifescience@trade.gov.uk

www.great.gov.uk

Hilary Glidden

Global Head of Life Sciences

Washington

+1 857 277 9793

Hilary.glidden@trade.gov.uk

Lois Gaden

Senior Manager, Biopharmaceuticals

London

+44 792 758 1207

Lois.gaden@trade.gov.uk

John Lownds

Senior Manager, Biopharmaceuticals

London

+44 787 654 6036

John.lownds@trade.gov.uk

Steve Kerr

Healthcare, Life Sciences & Bioeconomy

Sector Lead, Scotland

+44 744 281 7037

Steve.kerr@trade.gov.uk

Connect with the Department for Business and Trade Team at BIO.

Contacts

Connect

Matt Clark

Senior Trade and Investment Officer, Life Sciences

British Consulate, Boston, USA

+1 617 245 4583

Matthew.clark@trade.gov.uk

Michael Callahan

Senior Trade and Investment Officer, Life Sciences

British Consulate, Boston, USA

+1 202 856 5658

Adrianna Gomez

Trade and Investment Officer, Life Sciences

British Consulate, Boston, USA

+1 617 283 7709

Adrianna.gomez@trade.gov.uk

Department for Business and Trade

We support growth by backing businesses in the UK and globally, promoting investment and championing free trade.

Disclaimer

Whereas every effort has been made to ensure that the information in this document is accurate, the Department of Business and Trade and the Contributors do not accept liability for any errors, omissions or misleading statements, and no warranty is given or responsibility accepted as to the standing of any individual, firm, company or other organisation mentioned.

© Crown copyright 2023

This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/ doc/ open-government-licence/version/3

Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

Published by Department for Business and Trade

May 2023